Carvedilol (Coreg) Pharmacology

Carvedilol, a beta-blocker marketed as Coreg, serves as a primary treatment for heart failure with reduced ejection fraction, though its use for isolated hypertension has declined per recent clinical guidelines. Unlike standard beta-blockers, Carvedilol possesses unique alpha-blocking activity, which contributes to its blood pressure-lowering efficacy and potentially reduces adverse respiratory impacts in patients with asthma or COPD. Clinical management requires careful titration to balance heart rate and blood pressure targets while monitoring for common side effects like sedation and sexual dysfunction. Abrupt discontinuation poses significant risks, including rebound ischemia and hypertensive crises, due to the drug’s seven-to-ten-hour half-life. Practitioners must also account for drug interactions, particularly with CYP2D6 and 2C9 inhibitors, and the medication's role as a P-glycoprotein inhibitor, which can elevate concentrations of drugs like colchicine.